Program Available Online

NEW YORK, NY – September 22, 2015 – The Cardiovascular Research Foundation (CRF) has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, October 12; Tuesday, October 13; Wednesday, October 14; and Thursday, October 15.

The complete agenda for TCT 2015 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site.

Media are invited to attend TCT. If you are unable to attend in person, you may still cover it remotely via Virtual TCT. Registering as media ensures that you have access to all of the press conferences, trial data, abstracts, and press releases. More information on press credentials and guidelines can be found at http://www.crf.org/tct/press/press-credentials-and-guidelines. To apply for press credentials, visit: http://www.crf.org/tct/press/press-registration-form.

TCT 2015 Press Conference Schedule

Monday, October 12, 2015

9:15 am – 10:30 am

Moderator: Roxana Mehran, MD

Discussants: Marie-Claude Morice, MD; Daniel I. Simon, MD; Pascal Vranckx, MD, PhD

 

9:15 am

A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention

Shigeru Saito, MD

9:30 am

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Run-Lin Gao, MD

9:45 am

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Dean J. Kereiakes, MD

10:00 am

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease – Two-Year Outcomes

Bernard R. Chevalier, MD

10:15 am

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold – Six-Month Clinical, Angiographic, and Imaging Outcomes         

Michael Haude, MD

 

Tuesday, October 13, 2015

9:00 am – 10:15 am

Moderator: Ori Ben-Yehuda, MD

Discussants: Bernard De Bruyne, MD, PhD; Nico H.J. Pijls, MD, PhD; Marco Valgimigli, MD, PhD

 

9:00 am

RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention  

Giora Weisz, MD

9:15 am

EXPLORE: A Prospective Randomized Trial of Chronic Total Occlusion Intervention Versus Medical Therapy After Successful Primary Angioplasty in Patients With ST-Segment Elevation Myocardial Infarction

Jose P.S. Henriques, MD

9:30 am

TOTAL: A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction – One-Year Outcomes             

Sanjit S. Jolly, MD, MSc

9:45 am

A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset  

Steffen Desch, MD

10:00 am             

PLATFORM: Quality-of-Life and Economic Outcomes of an FFR-CT Diagnostic Strategy in Patients With Suspected Coronary Artery Disease 

Mark Andrew Hlatky, MD

 

Wednesday, October 14, 2015

9:00 am – 10:15 am

Moderator: George D. Dangas, MD, PhD

Discussants: TBD

 

9:00 am

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding             

Philip M. Urban, MD

9:15 am

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease              

Upendra Kaul, MD

9:30 am

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

Xu Bo, MD

9:45 am

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis        

Robert A. Byrne, MB, BCh, PhD

10:00 am

IN.PACT SFA: A Prospective Randomized Trial of a Drug-Coated Balloon for Femoropopliteal Lesions – Two-Year Outcomes

John R. Laird Jr, MD

 

Thursday, October 15, 2015

9:00 am – 10:15 am

Moderator: Ajay J. Kirtane, MD, SM

Discussants: Samir R. Kapadia, MD; Roxana Mehran, MD; Jeffrey J. Popma, MD

 

9:00 am

BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement    

Thierry Lefevre, MD

9:15 am

SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes

Howard C. Herrmann, MD

9:30 am

RESPECT: A Prospective Randomized Trial of PFO Closure In Patients With Cryptogenic Stroke - Long-Term Results          

John D. Carroll, MD

9:45 am

Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis           

Tomohiko Taniguchi, MD

10:00 am

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves        

Danny Dvir, MD

 

Receive updates on Twitter: https://twitter.com/TCTConference.